US trade report names countries that fail to adequately protect pharma IPR
This article was originally published in SRA
The Office of the US Trade Representative has expressed growing concern over problems faced by American pharmaceutical companies in accessing certain markets, particularly in Algeria and Indonesia1,2 In the trade watchdog’s 2009 Special 301 Report, both nations have been elevated to the Priority Watch List, which identifies countries with serious intellectual property problems requiring increased bilateral attention.
You may also be interested in...
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.